Imagine a global early-warning system that tracks how viruses like COVID-19 and mpox change over time. It focuses on people who are often overlooked in medical trials, like kids and expecting mothers. By connecting doctors across 18 countries, it spots dangerous new strains before they cause a massive crisis.
Vaccine and treatment developers lack real-time, high-quality data on how new viral variants affect children and pregnant women. This leads to delayed product approvals and suboptimal clinical management during outbreaks.
A global network of 30 cohort studies and a set of 9 deliverables providing evidence-based recommendations for managing COVID-19 and mpox.
If you are a vaccine developer dealing with rapid viral mutations — this project developed a global network of cohort studies that provides evidence on vaccine effectiveness. This allows for faster updates to vaccine formulas for children and pregnant women.
If you are a clinic provider dealing with unpredictable infection outbreaks — this project developed evidence-based recommendations for clinical management. This helps in optimizing treatment strategies for the most at-risk pediatric groups.
If you are a software firm dealing with poor data on emerging threats — this project developed a coordinated research response across 30 centers of excellence. This provides the real-world data needed to build more accurate outbreak prediction models.
Based on available project data, no pricing or cost structure for the results is mentioned as it is a Horizon-RIA research project.
The project already operates at a significant scale, utilizing 30 centers of excellence across 18 countries to track viral variants.
Based on available project data, specific IP or licensing terms are not provided; the goal is to deliver evidence-based recommendations for public health.
It integrates by building on existing and new cohorts, ranging from large-scale national administrative health datasets to regional infection-specific cohorts.
The project period runs from 2021-11-01 to 2025-10-31.
The consortium is heavily academic, with 19 universities and 7 research institutions, reflecting a strong focus on data generation. However, the inclusion of 3 industry partners and 2 SMEs suggests a bridge toward commercial application. The geographical reach is impressive, spanning 18 countries including the US, Thailand, and South Africa, which provides a high-value, diverse dataset for any health-related business.
Contact Universita Degli Studi di Padova regarding the VERDI cohort network.
Contact us to identify specific data-sharing opportunities with the VERDI consortium.
